## mRNA-1273.351

Pre0print published April 2021
<https://www.biorxiv.org/content/10.1101/2021.04.13.439482v1>

> Here, we present the initial evaluation in mice of two updated COVID-19 mRNA vaccines designed to target emerging SARS-CoV-2 variants: 
> (1) monovalent mRNA-1273.351 encodes for the S protein found in the B.1.351 lineage and 
> (2) mRNA-1273.211 comprising a 1:1 mix of mRNA-1273 and mRNA-1273.351. 

> Like mRNA-1273, mRNA-1273.351 encodes the prefusion stabilized S protein of SARS-CoV-2; however, in contrast to mRNA-1273, mRNA-1273.351 incorporates key mutations present in the B.1.351 variant, including L18F, D80A, D215G, Î”242-244, R246I, K417N, E484K, N501Y, D614G, A701V (Figure 1).

List of variants from table 1. B.1.351 (501Y .V2) that are used to modify mRNA-1273 to mRNA-1273.351. 

* L18F
* D80A
* D215G
* 242-244del
* R246I
* K417N
* E484K
* N501Y
* D614G
* A701V

Note the nomenclature for 242-244del is the correct description instead of 241-243del (as used for some vaccine strain reporting)
according to HGVS 
> "for all descriptions the most C-terminal position possible of the reference sequence is arbitrarily assigned to have been changed (3' rule)".

| Seq  | Nomenclature |
|:---:|:---:|
| LLAL | Ref p.241-244 |
| L--- | p.242-244del |
| ---L | p.241-243del |

The sequence was reproduced by modifying our fasta for 
mRNA-1273_vaccine_translated with this list of variant from B.1.351 as described by the authors.

>mRNA-1273.351
MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTL---HISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT

